Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
We performed a multicenter, randomized, double-blind, placebo-controlled 28-week trial. 300
non-diabetic obese subjects or overweight subjects with co-morbidities were randomly
assigned. Eligible participants were randomized 2:1 to once-daily subcutaneous injections of
either liraglutide or placebo. The primary outcome is to investigate the composition of the
gut microbiota from baseline to end of treatment.